Clinical characteristics of mastocytosis patients with and without α-tryptase encoding TPSAB1 gain
| Clinical characteristics . | No HαT (n = 149) . | HαT (n = 31) . | P . |
|---|---|---|---|
| Age at diagnosis, median (range), y | 48 (11-91) | 47 (20-72) | .845 |
| Sex, female/male, n | 84/65 | 14/17 | .322 |
| Mast cell infiltration (% BM histology), median (range) | 10 (0-80) | 5 (1-60) | .207 |
| KIT D816V mutation, n (% positive) | 132/147 (89.9) | 28/30 (93.3) | .741 |
| KIT D816V mutant allele burden, median (range), % | 0.267 (0-46.9) | 0.021 (0.002-10.38) | .001 |
| Serum tryptase level, median (range), ng/mL | 34.5 (1.8-1090) | 49.6 (11.9-1617) | .004 |
| Presence of associated hematologic neoplasm, n (%) | 16 (10.7) | 3 (9.7) | 1.000 |
| Allergy, n (% positive) | 28/142 (19.7) | 11/30 (36.7) | .055 |
| Hymenoptera venom allergy | 14/28 (50) | 9/11 (81.8) | .007 |
| Pollen allergy | 3/28 (10.7) | 1/11 (9.1) | n.t. |
| Drug allergy | 8/28 (28.6) | 1/11 (9.1) | n.t. |
| Food allergy | 6/28 (21.4) | 1/11 (9.1) | n.t. |
| Other type of allergy | 3/28 (10.7) | 0/11 (0) | n.t. |
| Mediator symptoms, n (% positive) | 62/146 (42.5) | 22/31 (71.0) | .005 |
| Skin symptoms | 23/62 (37.1) | 6/22 (27.3) | n.t. |
| Cardiovascular symptoms | 28/62 (45.2) | 14/22 (63.6) | .004 |
| Gastrointestinal symptoms | 19/62 (30.6) | 4/22 (18.2) | n.t. |
| Skeletal symptoms | 7/62 (11.3) | 0/22 (0) | n.t. |
| Neurologic symptoms | 11/62 (17.7) | 3/22 (13.6) | n.t. |
| Clinical characteristics . | No HαT (n = 149) . | HαT (n = 31) . | P . |
|---|---|---|---|
| Age at diagnosis, median (range), y | 48 (11-91) | 47 (20-72) | .845 |
| Sex, female/male, n | 84/65 | 14/17 | .322 |
| Mast cell infiltration (% BM histology), median (range) | 10 (0-80) | 5 (1-60) | .207 |
| KIT D816V mutation, n (% positive) | 132/147 (89.9) | 28/30 (93.3) | .741 |
| KIT D816V mutant allele burden, median (range), % | 0.267 (0-46.9) | 0.021 (0.002-10.38) | .001 |
| Serum tryptase level, median (range), ng/mL | 34.5 (1.8-1090) | 49.6 (11.9-1617) | .004 |
| Presence of associated hematologic neoplasm, n (%) | 16 (10.7) | 3 (9.7) | 1.000 |
| Allergy, n (% positive) | 28/142 (19.7) | 11/30 (36.7) | .055 |
| Hymenoptera venom allergy | 14/28 (50) | 9/11 (81.8) | .007 |
| Pollen allergy | 3/28 (10.7) | 1/11 (9.1) | n.t. |
| Drug allergy | 8/28 (28.6) | 1/11 (9.1) | n.t. |
| Food allergy | 6/28 (21.4) | 1/11 (9.1) | n.t. |
| Other type of allergy | 3/28 (10.7) | 0/11 (0) | n.t. |
| Mediator symptoms, n (% positive) | 62/146 (42.5) | 22/31 (71.0) | .005 |
| Skin symptoms | 23/62 (37.1) | 6/22 (27.3) | n.t. |
| Cardiovascular symptoms | 28/62 (45.2) | 14/22 (63.6) | .004 |
| Gastrointestinal symptoms | 19/62 (30.6) | 4/22 (18.2) | n.t. |
| Skeletal symptoms | 7/62 (11.3) | 0/22 (0) | n.t. |
| Neurologic symptoms | 11/62 (17.7) | 3/22 (13.6) | n.t. |
n.t., not tested.